Our company has partnered with Huizhi Heyuan Biotechnology (Suzhou) Co., Ltd. to establish a full-chain GMP manufacturing platform for CGT products spanning plasmids, viral vectors and cells. Equipped with clean-grade production workshops and manufacturing systems, the platform covers the construction of recombinant engineered cell lines and preparation of primary therapeutic CAR-T cells. Stable commercial production is achieved via cell sorting, ex vivo expansion and full-process aseptic control.

Huizhi Heyuan also operates a 3,500 m² animal testing center housing laboratory animal species including mice, dogs, non-human primates, pigs, rabbits and alpacas. The facility supports a complete suite of preclinical studies, such as in vivo pharmacology and efficacy evaluation, repeat-dose toxicology, biodistribution and immunogenicity safety assessment.

We adhere to pharmacopoeia standards and GMP quality control requirements throughout all workflows. Core raw materials feature traceability and scalable high-purity production, meeting the specifications for genetic modification and preclinical research.